Inhibikase Therapeutics Inc (IKT)
$1.55 -7.19% Close Oct 30, 2026 Live
Inhibikase Therapeutics stock today
Inhibikase Therapeutics closed at $1.55 on October 30, 2026, down 7.19% on the day. Over the past year it returned +6.2% with dividends reinvested, against +12.4% for the S&P 500. Its market value is $205 million.
$1.50$2.00$2.50
NovJan 2026MarMayJulSep
| Period | IKT | S&P 500 (SPY) |
|---|---|---|
| 1 month | -24.6% | -0.9% |
| 3 months | -32.0% | +2.1% |
| Year to date | -24.4% | +11.7% |
| 1 year | +6.2% | +12.4% |
| 3 years | +78.2% | +88.5% |
| 5 years | -87.0% | +76.0% |
Key statistics
- Market value
- $205M
- 52-week range
- $1.41 to $2.52
- Next report
- Nov 13, 2026 (estimated)
About Inhibikase Therapeutics
Biopharmaceutical company developing treatments for neurological diseases.
Sector: Health Care
More on Inhibikase Therapeutics
- Financials: revenue, earnings and segmentsRevenue +111% in the year to Dec 2023
- Returns: what $1,000 became$1,000 five years ago is $129.82 today
No forecast, no recommendation. This page describes Inhibikase Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.